Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,799 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07568184Recruiting
New Exosome Treatment for Sudden Hearing Loss
This trial tests a new way to deliver anti-inflammatory medicine directly into the ear using tiny particle carriers called exosomes. It's designed for people who lost hearing suddenly without a clear cause and didn't improve with standard steroid pills.
Kafr ash Shaykh, EgyptAges 18–65 - NCT07570563RecruitingPhase 1/Phase 2
T Cell Immunotherapy for Advanced Cancers
This study tests a new immunotherapy using specially engineered immune cells (called TCR-enhanced Vδ2 T cells) to treat blood cancers or solid tumors that haven't responded to standard treatments. The goal is to see if these cells can safely shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–75 - NCT07575984RecruitingPhase 4
Mexidol Safety and Efficacy for Acute Ischemic Stroke
This trial tests whether Mexidol, a medication that may protect brain tissue, can help people recover better after an acute ischemic stroke (a type of stroke caused by a blood clot). The study includes stroke patients and healthy volunteers to understand how the drug works and if it's safe.
ArkhangelskAges 18–90 - NCT07579234RecruitingPhase 3
New drug F182112 for hard-to-treat multiple myeloma
This trial tests a new drug called F182112 against standard treatments for multiple myeloma that has stopped responding to previous therapies. The goal is to see if F182112 works better and is safe for patients whose cancer has become resistant to multiple drug classes.
TianjingAges 18 years+ - NCT07581210RecruitingPhase 2
QD202 Study for Recent Stroke Treated With Clot-Busting Medicine
This study tests whether a new drug called QD202 can help protect the brain and improve recovery when given alongside standard clot-busting therapy (thrombolysis) for acute ischemic stroke. You would be in the trial if you had a stroke in the last 24 hours and are receiving or planning to receive thrombolytic treatment.
Meizhou, GuangdongAges 18–85 - NCT07581834RecruitingPhase 2
Dalpiciclib plus hormone therapy for early hormone-positive breast cancer
This study tests whether adding a new drug called dalpiciclib to standard hormone therapy improves outcomes for women with early-stage breast cancer that is hormone-receptor positive. The goal is to see if this combination is more effective and safe than hormone therapy alone.
Fuzhou, FujianAges 18 years+ - NCT07583706Recruiting
Ultra-minimally invasive prostate dilation for BPH symptoms
This study tests a new, minimally invasive procedure to relieve urinary symptoms caused by an enlarged prostate (benign prostatic hyperplasia or BPH). The procedure gently dilates (widens) the prostate to improve urine flow and reduce bothersome symptoms like frequent urination and weak stream.
BeijingAges 40–80 - NCT07584499RecruitingPhase 1
New drug test for children with EGFR-positive solid tumors
This study tests a new cancer drug called Becotatug Vedotin in children ages 2–18 with certain types of solid tumors (cancers that form in organs or tissues) that have an EGFR protein. The drug is designed to find tumors with this protein and attack cancer cells while sparing healthy ones.
Guangzhou, GuangdongAges 2–18 - NCT07584889RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Relapsed Blood Cancers
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
Shenzhen, Other (Non U.s.)Ages 18–75 - NCT07585032Recruiting
Ultrasound-guided heat treatment for pancreatic insulinoma tumors
This trial tests a minimally invasive procedure that uses heat (delivered through an ultrasound scope) to treat insulinoma—a hormone-producing pancreatic tumor that causes low blood sugar. The procedure may offer a less invasive alternative to surgery.
GothenburgAges 15–80 - NCT07586891Recruiting
Low-Branched-Chain Amino Acid Diet With Immunotherapy for Stage III Melanoma
This trial tests whether a special diet low in certain amino acids (building blocks of protein), combined with an immune-boosting antibody drug, can safely shrink stage III melanoma that has spread to lymph nodes. The goal is to see if this combination works better than standard treatment.
Xi'anAges 18–75 - NCT07586904RecruitingEarly Phase 1
New Immunotherapy Combination for Advanced Melanoma
This trial tests a combination of two drugs (cadonilimab and interferon) given before surgery to treat advanced melanoma that has spread to nearby lymph nodes or one distant site. The goal is to shrink tumors and improve chances of successful surgery and long-term survival.
Xi'anAges 18–75 - NCT07588243Recruiting
Ultrasound Device Study for Hair Regrowth
This trial tests a new ultrasound device designed to help regrow hair in people with male or female pattern baldness. The study evaluates whether the device is safe and effective at promoting hair growth over time.
Glenview, IllinoisAges 22–70 - NCT07589647Recruiting
Brain Stimulation for Bipolar Disorder and Weight Management
This study tests whether a small electrical stimulation device targeting a specific brain region (the suprachiasmatic nucleus) can help improve metabolic health and weight in people with stable bipolar disorder who also have obesity. The goal is to see if this approach is safe and effective.
Hangzhou, ZhejiangAges 18–45 - NCT07596394Recruiting
Registry of Catheter-Based Aortic Valve Replacements
This registry collects information about patients who receive a new valve inserted through a catheter (a thin tube) rather than open surgery. It tracks how well the procedure works and any side effects to help doctors understand the long-term safety and effectiveness of this less invasive approach.
Pavia, PaviaAges 18 years+ - NCT07599371RecruitingPhase 1/Phase 2
Ivoximab and temozolomide for recurring brain tumors
This trial tests a combination of two drugs—ivoximab (a new immunotherapy) and temozolomide (chemotherapy)—to treat gliomas (brain tumors) that have come back or stopped responding to prior treatment. The goal is to see if this combination is safe and effective.
Zhengzhou, HenanAges 18–85 - NCT07603752Recruiting
Brain implant to restore arm movement in spinal cord injury
This trial tests a wireless implant placed on the brain's surface to help people with cervical (neck-level) spinal cord injuries regain some arm and hand movement. The device reads brain signals and sends them to muscles, potentially bypassing the damaged spinal cord.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07604805Recruiting
Chinese herbal medicine for severe lung blood pressure
This trial tests whether Qishen Yiqi Dropping Pills, a traditional Chinese herbal medicine, can safely improve symptoms and heart function in people with severe pulmonary hypertension (abnormally high blood pressure in the lungs). You would take this medicine alongside or instead of other treatments to see if it helps you walk farther and feel better.
Guangzhou, GuagdongAges 18–75 - NCT07604896RecruitingPhase 4
Lecanemab for early Alzheimer's disease with amyloid buildup
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
Wenzhou, ZhejiangAges 50–90 - NCT07605845RecruitingPhase 1
Testing GL-2045 Safety in Immune Thrombocytopenia Patients
This trial tests a new drug called GL-2045 for immune thrombocytopenia (ITP)—a condition where your body destroys its own platelets, causing low platelet counts and bleeding risks. The study checks if GL-2045 is safe and effective for people whose platelet counts haven't been controlled well enough with other treatments.
LeedsAges 18–80 - NCT07608978RecruitingPhase 2
New drug combination for untreated aggressive lymphoma
This study tests a combination of five drugs (including a targeted therapy called polatuzumab vedotin) for patients with a specific type of aggressive lymphoma (DLBCL) that has never been treated before. The goal is to see if this combination works better and is safe for certain subtypes of this cancer.
Nanjing, JiangsuAges 18 years+ - NCT07610551Recruiting
Combination therapy for advanced liver cancer
This trial studies whether combining three treatments—an immunotherapy drug (Atezo), a blood-vessel-blocking drug (Bev), and a radioactive bead treatment (SIRT-Y90)—can help patients with advanced liver cancer that cannot be surgically removed. The goal is to see if using all three together works better than using fewer treatments.
Xi’an, ShanxiAges 18 years+ - NCT07612280RecruitingPhase 1/Phase 2
Testing JBI-802 for blood cell disorders with high platelets
This study tests a new oral medication called JBI-802 to treat rare bone marrow disorders (myeloproliferative and myelodysplastic neoplasms) that cause abnormally high platelet counts. The goal is to evaluate whether the drug is safe and can help lower platelet levels and control disease.
Sydney, New South WalesAges 18 years+ - NCT07614061RecruitingPhase 1
Cell therapy for advanced bile duct cancer
This trial tests a new treatment called BTC-Ag-T, which uses your own immune cells enhanced in the lab to fight advanced biliary tract cancer (cancer of the bile ducts or gallbladder). It's designed for patients whose cancer has spread or cannot be surgically removed and who have already received standard chemotherapy plus immunotherapy.
ShanghaiAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,799 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.